scout
Opinion|Videos|December 15, 2023

KEYNOTE-522: Event-Free Survival With Neoadjuvant and Adjuvant Pembrolizumab in TNBC

Medical oncologists discuss recent data from KEYNOTE-522 looking at event-free survival with neoadjuvant and adjuvant pembrolizumab in triple-negative breast cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME